Compare Global X SuperDividend ETF (SDIV) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X SuperDividend ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? Global X SuperDividend ETF trades at $24.87, while Vertex Pharmaceuticals Incorporated trades at $478.06 (market cap $121.95B). The key difference: Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Global X SuperDividend ETF nearer its low. Which is the better fit depends on your goals.
| SDIV | VRTX | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $26.34 | $529.59 |
52-Week Low | $22.90 | $366.54 |
Market Cap | — | $121.95B |
Enterprise Value | — | $116.69B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X SuperDividend ETF
SDIV is an ETF that invests in 100 of the highest dividend-yielding equity securities in the world. The fund seeks to provide a high level of income to investors by selecting companies from both developed and emerging markets that have historically provided high dividend yields. By diversifying globally, SDIV aims to mitigate risks associated with focusing on a single country, while offering monthly distributions to its shareholders.
Read more on SDIV →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
